Drug Profile
Pegaspargase biosimilar - Primrose Bio
Alternative Names: PF690Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 28 Apr 2022 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (IM, Injection)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (IV, Injection)